Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibiotic-associated diarrhoea (AAD) is a frequent complication of systemic antibiotic therapy and Clostridium difficile-associated diarrhoea (CDAD) is its most serious form due to associated morbidity and mortality. AIM: This trial aimed to investigate whether the probiotic VSL#3 prevents AAD and CDAD in average-risk hospital patients. METHODS: Adult hospital inpatients exposed to systemic antibiotics were recruited to this multicentre, randomized, double-blind, placebo-controlled trial. One sachet of VSL#3 or placebo was given twice daily for the length of the antibiotics course and for seven days thereafter. Primary outcomes were AAD and CDAD. FINDINGS: Patients randomized to active (N = 117) and placebo (N = 112) groups were well-matched for baseline demographic patient data. No cases of CDAD were detected. The rate of AAD was significantly lower in the active group on per protocol analysis (0% active vs 11.4% placebo; P = 0.006). On intention-to-treat analysis the difference in AAD incidence (4.3% active vs 8.9% placebo; P = 0.19) was not significant. CONCLUSIONS: VSL#3 is associated with a significant reduction in the incidence of AAD in average-risk hospital inpatients exposed to systemic antibiotics. As the incidence of CDAD has fallen sharply, no cases of CDAD were found. Probiotic administration as prophylaxis for CDAD may not be indicated in average-risk hospital patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Newberry, S. J. (2012) · JAMA · doi:10.1001/jama.2012.3507 · Cited by 870 · cited 1×
“) can prevent AAD in patients exposed to systemic antibiotics.(1,9,10) The evidence for CDAD preventions is, however, inconclusive as the few published trials have shown conflicting results, and are not applicable to the average-risk patient due to strict exclusion criteria.”
ResultHickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., & Bulpitt, C. J. (2007) · BMJ · doi:10.1136/bmj.39231.599815.55 · Cited by 599 · cited 11×
“Recruiting very high-risk patients to this trial proved difficult, but this is common in CDAD prevention trials.(11,12,17) Due to the lack of any CDAD cases in this trial, the question whether VSL#3 can prevent CDAD in principle remains unanswered.”
BackgroundMethodResultInfluential
Cited by
Actinobacteria: A relevant minority for the maintenance of gut homeostasis
Binda, C., Lopetuso, L. R., Rizzatti, G., Gibiino, G., Cennamo, V., & Gasbarrini, A. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.02.012 · Cited by 815
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., Guyatt, G. H., & Johnston, B. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub3 · Cited by 741
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K.-F., Beardsley, J., Mertz, D., & Johnston, B. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub4 · Cited by 550
Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
Tojo, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15163 · Cited by 533
The gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Bifidobacteria and Their Health-Promoting Effects
Hidalgo-Cantabrana, C., Delgado, S., Ruiz, L., Ruas-Madiedo, P., Sánchez, B., & Margolles, A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0010-2016 · Cited by 490
“Recently, Boltin and co-workers (118) reviewed the use of probiotics for H. pylori - induced ulcer disease; they concluded that the use of probiotics alone is not enough to eradicate H. pylori , but it is suitable to improve the ef fi cacy of antibiotic regimens for H. pylori eradication and prevent AAD.”
BackgroundInfluentialShen, N. T., Maw, A., Tmanova, L. L., Pino, A., Ancy, K., Crawford, C. V., Simon, M. S., & Evans, A. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.003 · Cited by 273
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Chamberlain, R., & Lau, C. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s98280 · Cited by 177
Ponziani, F. R., Zocco, M. A., D’Aversa, F., Pompili, M., & Gasbarrini, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i25.4491 · Cited by 168
Goodman, C., Keating, G., Georgousopoulou, E., Hespe, C., & Levett, K. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043054 · Cited by 163
Probiotic mixture VSL# 3: An overview of basic and clinical studies in chronic diseases
Cheng, F.-S., Pan, D., Chang, B., Jiang, M., & Sang, L.-X. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i8.1361 · Cited by 147
McFarland, L. (2015) · Antibiotics · doi:10.3390/antibiotics4020160 · Cited by 109
“VSL#3 mixed, 75% pen 9 × 10(11) duration + 1 week 3 weeks 0/117 (0%) ns 0/112 (0%) Selinger 2013 [15]”
Jafarnejad, S., Shab‐Bidar, S., Speakman, J. R., Parastui, K., Daneshi‐Maskooni, M., & Djafarian, K. (2016) · Nutrition in Clinical Practice · doi:10.1177/0884533616639399 · Cited by 68
Johnston, B. C., Lytvyn, L., Lo, C. K.-F., Allen, S. J., Wang, D., Szajewska, H., Miller, M., Ehrhardt, S., Sampalis, J., Duman, D. G., et al. (2018) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2018.84 · Cited by 50
Self-citationSegui-Perez, C., Huang, L. Z. X., Paganelli, F. L., Lievens, E., & Strijbis, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-92125-2 · Cited by 45
“In the adult intestine, Bifidobacterium species support the growth of other commensals 17–19 , modulate T-regulatory responses 20 , improve symptoms of several gastrointestinal conditions 21 and prevent antibiotic-associated diarrhea 22,23 .”
Metadata
- Authors
- Selinger, C. P., Bell, A., Cairns, A., Lockett, M., Sebastian, S., & Haslam, N.
- Venue
- Journal of Hospital Infection
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 84
- Issue
- 2
- Pages
- 159-165
- ISSN
- 0195-6701 (ISSN-L)
- OpenAlex
- W1980156274
- Cited by
- 93
- References
- 2
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.